Mycoplasma Testing Market Share, Growth, Demand and Future Revenue 2032

Mycoplasma Testing Market Size- By Technology, By Product & Services, By Distribution Channel, By Application, By End Use- Regional Outlook, Competitive Strategies and Segment Forecast to 2032

Mycoplasma Testing Market Size- By Technology, By Product & Services, By Distribution Channel, By Application, By End Use- Regional Outlook, Competitive Strategies and Segment Forecast to 2032

Published: Dec 2022 Report ID: HLCA2230 Pages: 1 - 233 Formats*:     
Category : Healthcare
Global Mycoplasma Testing Market Overview:

According to SPER Market Research, the Global Mycoplasma Testing Market is estimated to reach USD 3.05 billion by 2032 with a CAGR of 13.43%. 

In essence, mycoplasma testing is a type of medical test done by medical experts to help you quickly identify or exclude mycoplasma contamination of your cell cultures. This strategy entails a series of examinations that evaluate the blood antibodies created in response to a mycoplasma infection or that directly identify the organism through culture or by detecting its genetic material (DNA) in a body sample. Mycoplasma contamination is a frequent and ongoing problem in many cell culture techniques used in life science research and the pharmaceutical industry. Mycoplasmas can reach high titers in culture medium without exhibiting typical bacterial contamination indications like turbidity. They result in chromosomal defects, reduced proliferation, and altered metabolism in cultured cells. In short, Mycoplasma infection compromises both the validity of data from damaged cell lines and the results of life science research. Therefore, Mycoplasma testing is essential for cell-based research and the manufacture of goods where consumer health is a top priority. This leads to the preservation of contamination-free cell cultures.

Impact of COVID-19 on the Global Mycoplasma Testing Market
Mycoplasma testing services are in high demand because to the corona virus pandemic and the discovery of Mycoplasma pneumoniae in SARS-CoV-2 patients. This is mostly because patients with pre-existing medical illnesses have difficulties such as cytokine, autoimmune activation and hemodynamic malfunction, mitochondrial dysfunction, and other symptoms that are difficult to treat. Mycoplasma have consistently been identified as co-infections in a wide range of clinical disorders, and in some cases, this has progressed to a lethal illness, according to investigations. Medical practitioners have recently been told by published studies that COVID-19 patients may additionally harbour Mycoplasma pneumoniae or other illnesses in addition to the COVID-19. In light of this, individuals who exhibit pneumonia symptoms according to COVID-19 should undergo mycoplasma testing. Such instances are predicted to raise interest in mycoplasma testing in diagnostic and pathological settings. It is expected that in the following months, demand for mycoplasma diagnostics will rise in a number of different countries throughout the world due to the rising prevalence of coinfections in COVID-19 patients, with a high probability that they were caused by Mycoplasma pneumonia.




Scope of the Report:
 Report Metric Details
 Market size available for years 2019-2032
 Base year considered 2021
 Forecast period 2022-2032
 Segments coveredBy Technology, By Product & Services, By Distribution Channel, By Application, By End Use
 Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East and Africa
 Companies CoveredAgilent Technologies, American Type Culture Collection, Asahi Kasei Medical Co. Ltd., Biological Industries Israel Beit Haemek Ltd., Bionique Testing Laboratories Inc., Biotools B & M Labs, Charles River Laboratories International Inc., Clongen Laboratories Inc., Creative Bioarray, Eurofins Scientific, GenBio,GeneCopoeia Inc., InvivoGen, Lonza Group Ltd., Merck KGaA, Meridian Bioscience Inc., Minerva Biolabs GmbH, Mycoplasma Experience, Nelson Laboratories Fairfield Inc., NorgenBiotek Corp., PromoCell GmbH, Roche Diagnostics, Sartorius AG, Savyon Diagnostics, ScienCell Research Laboratories Inc.,Thermo Fisher Scientific Inc.
Global Mycoplasma Testing Market Segmentation:

By Technology: Based on the Technology, Global Mycoplasma Testing Market issegmented as; Direct Assay, DNA Staining, ELISA, Enzymatic Methods, Indirect Assay, PCR, Others.

By Product & Services: Based on the Product& Services, Global Mycoplasma Testing Market is segmented as;Assays, Kits, & Reagents (Elimination Kits, ELISA Assays, Kits, & Reagents, Nucleic Acid, Detection Kits, PCR Assay, Stains, Standards & Controls, Others), Instruments, Services.

By Distribution Channel: 
Based on the Distribution Channel, Global Mycoplasma Testing Market is segmented as; Direct Tenders, Retail.
Global Mycoplasma Testing Market, By Application:
Based on the Application, Global Mycoplasma Testing Market is segmented as;Cell Line Testing, End-Of-Production Cell Testing, Virus Testing, Others.

By End Use: Based on the End Use, Global Mycoplasma Testing Market is segmented as;Academic Research Institutes, Cell Banks & Laboratories, Clinics, Community Healthcare, Contract Research Organizations, Hospitals and Surgical Centers, Oncology Centers, Pharmaceutical & Biotechnology Companies, Others.

By Region: North America owns the prime share of this market; the major factors of the market's growth in the region is this industry is anticipated to gain its market share because of its well-established healthcare industry and the rising prevalence of respiratory ailments. Additional reasons supporting the rise of this region include the presence of global pharmaceutical and biotech businesses as well as significant investments in R&D operations in the area. Due to rising healthcare expenditure and the need for better infrastructure for laboratory and clinical research, Asia Pacific is expected to see an exponential CAGR throughout the anticipated time period. Additionally, healthcare organisations' regulatory policies supporting enhancements in bio - safety quality are projected to stimulate future development prospects.
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation

3. Executive Summary

4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges 
4.2. COVID-19 Impacts of the Global Mycoplasma Testing Market

5. Market variables and outlook
5.1. SWOT analysis 
5.1.1 Strengths 
5.1.2 Weaknesses 
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis 
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape 
5.2.4 Technological landscape 
5.2.5 Environmental landscape 
5.2.6 Legal landscape 
5.3. PORTER’S five forces analysis 
5.3.1 Bargaining power of suppliers 
5.3.2 Bargaining power of Buyers 
5.3.3 Threat of Substitute 
5.3.4 Threat of new entrant 
5.3.5 Competitive rivalry
5.4. Heat map analysis

6. Global Mycoplasma Testing Market, By Technology, 2019-2032 (USD Million)
6.1. Direct Assay
6.2. DNA Staining
6.3. ELISA
6.4. Enzymatic Methods
6.5. Indirect Assay
6.6. PCR 
6.7. Others

7. Global Mycoplasma Testing Market, By Product& Services, 2019-2032 (USD Million)
7.1. Assays, Kits& Reagents
7.1.1. Elimination Kits
7.1.2. ELISA Assays, Kits, & Reagents
7.1.3. Nucleic Acid Detection Kits
7.1.4. PCR Assay
7.1.5. Stains
7.1.6. Standards & Controls
7.1.7. Others
7.2. Instruments
7.3. Services

8. Global Mycoplasma Testing Market, By Distribution Channel, 2019-2032 (USD Million)
8.1. Direct Tenders
8.2. Retail

9. Global Mycoplasma Testing Market,By Application, 2019-2032 (USD Million)
9.1. Cell Line Testing
9.2. End-Of-Production Cell Testing
9.3. Virus Testing
9.4. Others

10. Global Mycoplasma Testing Market, By End Use, 2019-2032 (USD Million)
10.1 Academic Research Institutes
10.2 Cell Banks & Laboratories 
10.3 Clinics
10.4 Community Healthcare
10.5 Contract Research Organizations
10.6 Hospitals and Surgical Centers
10.7 Oncology Centers
10.8 Pharmaceutical & Biotechnology Companies
10.9 Others

11. Global Mycoplasma Testing Market, By Region, 2019-2032 (USD Million)
11.1 North America
11.1.1. United States
11.1.2. Canada
11.1.3. Mexico
11.2 Europe
11.2.1. Germany
11.2.2. United Kingdom
11.2.3. France
11.2.4. Italy
11.2.5. Spain
11.2.6. Rest of Europe
11.3 Asia-Pacific
11.3.1. China
11.3.2. Japan
11.3.3. India
11.3.4. Australia
11.3.5. South Korea
11.3.6. Rest of Asia-Pacific
11.4 South America
11.4.1. Brazil
11.4.2. Argentina
11.4.3. Rest of South America
11.5 Middle East & Africa
11.5.1. Kingdom of Saudi Arabia 
11.5.2. United Arab Emirates
11.5.3. Rest of Middle East & Africa

12. Company Profiles
12.1 Agilent Technologies
12.1.1. Company details 
12.1.2. Financial outlook
12.1.3. Product summary 
12.1.4. Recent developments

12.2 American Type Culture Collection
12.2.1. Company details 
12.2.2. Financial outlook
12.2.3. Product summary 
12.2.4. Recent developments

12.3 Asahi Kasei Medical Co. Ltd.
12.3.1. Company details 
12.3.2. Financial outlook
12.3.3. Product summary 
12.3.4. Recent developments

12.4 Biological Industries Israel Beit Haemek Ltd.
12.4.1. Company details 
12.4.2. Financial outlook
12.4.3. Product summary 
12.4.4. Recent developments

12.5 Bionique Testing Laboratories Inc.
12.5.1. Company details 
12.5.2. Financial outlook
12.5.3. Product summary 
12.5.4. Recent developments

12.6 Biotools B & M Labs
12.6.1. Company details 
12.6.2. Financial outlook
12.6.3. Product summary 
12.6.4. Recent developments

12.7 Charles River Laboratories International Inc.
12.7.1. Company details 
12.7.2. Financial outlook
12.7.3. Product summary 
12.7.4. Recent developments

12.8 Clongen Laboratories Inc.
12.8.1. Company details 
12.8.2. Financial outlook
12.8.3. Product summary 
12.8.4. Recent developments

12.9 Creative Bioarray
12.9.1. Company details 
12.9.2. Financial outlook
12.9.3. Product summary 
12.9.4. Recent developments

12.10 Eurofins Scientific
12.10.1. Company details 
12.10.2. Financial outlook
12.10.3. Product summary 
12.10.4. Recent developments

12.11 GenBio
12.11.1. Company details 
12.11.2. Financial outlook
12.11.3. Product summary 
12.11.4. Recent developments

12.12 GeneCopoeia Inc.
12.12.1. Company details 
12.12.2. Financial outlook
12.12.3. Product summary 
12.12.4. Recent developments

12.13 InvivoGen
12.13.1. Company details 
12.13.2. Financial outlook
12.13.3. Product summary 
12.13.4. Recent developments

12.14 Lonza Group Ltd.
12.14.1. Company details 
12.14.2. Financial outlook
12.14.3. Product summary 
12.14.4. Recent developments

12.15 Merck KGaA
12.15.1. Company details 
12.15.2. Financial outlook
12.15.3. Product summary 
12.15.4. Recent developments

12.16 Meridian Bioscience Inc.
12.16.1. Company details 
12.16.2. Financial outlook
12.16.3. Product summary 
12.16.4. Recent developments

12.17 Minerva Biolabs GmbH
12.17.1. Company details 
12.17.2. Financial outlook
12.17.3. Product summary 
12.17.4. Recent developments

12.18 Mycoplasma Experience
12.18.1. Company details 
12.18.2. Financial outlook
12.18.3. Product summary 
12.18.4. Recent developments

12.19 Nelson Laboratories Fairfield Inc.
12.19.1. Company details 
12.19.2. Financial outlook
12.19.3. Product summary 
12.19.4. Recent developments

12.20 NorgenBiotek Corp.
12.20.1. Company details 
12.20.2. Financial outlook
12.20.3. Product summary 
12.20.4. Recent developments

12.21 PromoCell GmbH
12.21.1. Company details 
12.21.2. Financial outlook
12.21.3. Product summary 
12.21.4. Recent developments

12.22 Roche Diagnostics
12.22.1. Company details 
12.22.2. Financial outlook
12.22.3. Product summary 
12.22.4. Recent developments

12.23 Sartorius AG
12.23.1. Company details 
12.23.2. Financial outlook
12.23.3. Product summary 
12.23.4. Recent developments

12.24 Savyon Diagnostics
12.24.1. Company details 
12.24.2. Financial outlook
12.24.3. Product summary 
12.24.4. Recent developments

12.25 ScienCell Research Laboratories Inc.
12.25.1. Company details 
12.25.2. Financial outlook
12.25.3. Product summary 
12.25.4. Recent developments

12.26 Thermo Fisher Scientific Inc.
12.26.1. Company details 
12.26.2. Financial outlook
12.26.3. Product summary 
12.26.4. Recent developments

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings.  The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

SPER-Methodology-1

SPER-Methodology-2

SPER-Methodology-3


Frequently Asked Questions About This Report
The Mycoplasma Testing Market is projected to reach USD 3.05 billion by 2032, growing at a CAGR of 13.43% during the forecast period.
The Mycoplasma Testing Market grew in market size from 2021. The Market is expected to reach USD 3.05 billion by 2032, at a CAGR of 13.43% during the forecast period.
The Mycoplasma Testing Market CAGR of 13.43% during the forecast period.
You can get the sample pages by clicking the link -Click Here
The Mycoplasma Testing Market size is USD 3.05 billion from 2022 to 2032.
The Mycoplasma Testing Market segment is Covered By Technology, By Product & Services, By Distribution Channel, By Application, By End Use.
The North America and Europe region is anticipated to have the highest market share in the Mycoplasma Testing Market.
Mycoplasma contamination is a frequent and ongoing problem in many cell culture techniques used in life science research and the pharmaceutical industry. Mycoplasmas can reach high titers in culture medium without exhibiting typical bacterial contamination indications like turbidity.
The key players in the market include Companies Covered Agilent Technologies, American Type Culture Collection, Asahi Kasei Medical Co. Ltd., Biological Industries Israel Beit Haemek Ltd., Bionique Testing Laboratories Inc., Biotools B & M Labs, Charles River Laboratories International Inc., Clongen Laboratories Inc., Creative Bioarray, Eurofins Scientific, GenBio,GeneCopoeia Inc., InvivoGen, Lonza Group Ltd., Merck KGaA, Meridian Bioscience Inc., Minerva Biolabs GmbH, Mycoplasma Experience, Nelson Laboratories Fairfield Inc., NorgenBiotek Corp., PromoCell GmbH, Roche Diagnostics, Sartorius AG, Savyon Diagnostics, ScienCell Research Laboratories Inc.,Thermo Fisher Scientific Inc.
Not able to find what you are looking for? Need customization in the existing report?
Click Here
PLACE AN ORDER
  • 15% off
     
    $ 4250
  • 20% off
             
    $ 5650
  • 25% off
         
    $ 7450
Pre-Purchase Inquiry
SEND AN INQUIRY
NEED CUSTOMIZATION?
Request Customization
CALL OR EMAIL US
US:
India:
Email:
100% Secure Payment

SPER American Express
SPER VISA
SPER Master Card
SPER Mestro
SPER Paypal
SPER CCAvenues

Join Our SPER Panel

Our Global Clients

Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
SPER-Astellas Pharma
SPER-Citi Bank
SPER-Microsoft
SPER-EY
SPER-Sanofi
SPER-p&g
SPER-Johnson & Johnson
SPER-SIEMENS
SPER-LOREAL
SPER-Pfizer
SPER-IPSOS
SPER-Heineken
SPER-IQVIA
SPER-Kankar IMRB
SPER-Astellas Pharma
SPER-Citi Bank
SPER-Microsoft
SPER-EY
SPER-Sanofi
SPER-p&g
SPER-Johnson & Johnson
SPER-SIEMENS
SPER-LOREAL
SPER-Pfizer
SPER-IPSOS
SPER-Heineken
SPER-IQVIA
SPER-Kankar IMRB

SPER

Market Research

We are the leading, full-service global market research and consulting company.

Certificates
iso-1 iso-1
Secure Payments
SPER Payment Options
Connect with us